NCT06208267 Tranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty
| NCT ID | NCT06208267 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Mary's Research Center, Canada |
| Condition | Postoperative Bleeding |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2025-08-20 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2025-08-20 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tranexamic acid (TXA) is an anti-fibrinolytic agent developed in the 1960s that has been safely used to reduce blood loss, transfusion rates and bleeding-associated mortality in trauma, obstetrics and orthopedic surgery, including hip fracture care and arthroplasty. The efficacy and safety profile of TXA has been extensively studied in numerous clinical trials and observational studies. Its wide range of applications, combined with its favourable risk-benefit ratio, has led to the incorporation of TXA into clinical guidelines and protocols worldwide. This RCT aims to compare the current standard dosing for TXA to additional TXA doses given orally post-operatively for THA and TKA patients. The goal is to compare the following between study groups: visible bleeding on post-operative dressing, mobilization (steps, amount of time moving around), pain (visual analog scale), function (Oxford hip and knee scales) and ROM at four to six weeks.
Eligibility Criteria
Inclusion Criteria: ° All adults undergoing primary TKA and THA at St-Mary's Hospital Exclusion Criteria: * Age \< 18 years * Known hypersensitivity or allergy to TXA * Previous history of thromboembolic disease * Active malignancy (all current cancers other than local skin cancer) * Significant renal disease (hematuria, dialysis, kidney transplant) * History of convulsions * Known defective colour vision * Inability or unwillingness to use MyMobility app * Unable to communicate in French or English
Contact & Investigator
Jennifer Mutch, MDCM, FRCSC
PRINCIPAL INVESTIGATOR
St. Mary's Hospital Centre
Frequently Asked Questions
Who can join the NCT06208267 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Postoperative Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06208267 currently recruiting?
Yes, NCT06208267 is actively recruiting participants. Contact the research team at j.mutch.ortho@gmail.com for enrollment information.
Where is the NCT06208267 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT06208267 clinical trial?
NCT06208267 is sponsored by St. Mary's Research Center, Canada. The principal investigator is Jennifer Mutch, MDCM, FRCSC at St. Mary's Hospital Centre. The trial plans to enroll 210 participants.